SCHEMBL6891951

SCHEMBL6891951

CC(C)(C)OC(=O)n1cc2ccccc2n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
BCHE P06276 1/20 0.41
GAA P10253 2/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
GPR119 Q8TDV5 2/20 0.38
NR1H2 P55055 3/20 0.38
KDM4E B2RXH2 2/20 0.37
ALDH1A1 P00352 2/20 0.37
SCD O00767 1/20 0.37
GBA1 P04062 2/20 0.37
GLA P06280 1/20 0.36
MAPT P10636 1/20 0.36
THRB P10828 1/20 0.36
HPGD P15428 1/20 0.36
HIF1A Q16665 1/20 0.36
CKS1B P61024 1/20 0.36
SKP1 P63208 1/20 0.36
SKP2 Q13309 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27769472 0.82 L3MBTL1 (0.44) MEN1KMT2ABCHERAB9AKDM4E
SCHEMBL20139620 0.81 ESR2 (0.42) MEN1KMT2ABCHEGAANPC1
SCHEMBL30886888 0.80 HDAC8 (0.39) NPC1RAB9ANR1H2SCDMAPT
SCHEMBL4166121 0.80 BACE1 (0.40) MEN1KMT2ANPC1RAB9ANR1H2
SCHEMBL6027073 0.79 KMT2A (0.43) MEN1KMT2AGAANPC1RAB9A
SCHEMBL1742673 0.79 BCHE (0.36) MEN1KMT2ABCHEGAANPC1
SCHEMBL24874054 0.77 ENPP2 (0.33) MEN1KMT2ABCHESCD
SCHEMBL476817 0.77 STS (0.39) MEN1KMT2ABCHEGAANPC1
SCHEMBL17631624 0.77 HDAC8 (0.39) MEN1KMT2ABCHEGAANPC1
SCHEMBL6337523 0.76 HDAC8 (0.39) MEN1KMT2ANPC1RAB9ANR1H2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-106170486-B Novel indazolecarboxamides, method for the production thereof, pharmaceutical preparations containing the same and use thereof for producing medicaments 拜耳医药股份有限公司 2019-01-15 CN disclosed
CN-103917524-B Bicyclic heterocycles ASTELLAS PHARMA INC. (JP) 2016-05-04 CN disclosed
US-20040048866-A1 Indazole derivatives that are activators of soluble guanylate cyclase ABBOTT LABORATORIES 2004-03-11 US disclosed
WO-2003076408-A2 INDAZOLE DERIVATIVES THAT ARE ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE ABBOTT LABORATORIES (US) 2003-09-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040048866-A1 Indazole derivatives that are activators of soluble guanylate cyclase GUCY1B1, GUCY1A1, GUCY1A2 MEN1 2433/4885KMT2A 4490/4885BCHE 2360/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.